Authors: Yasuhide Kitagawa Satoru Ueno Kouji Izumi Yoshifumi Kadono Atsushi Mizokami Shiro Hinotsu Hideyuki Akaza Mikio Namiki
Publish Date: 2015/06/19
Volume: 34, Issue: 3, Pages: 319-327
Abstract
To investigate the clinical outcomes of metastatic prostate cancer patients and the relationship between nadir prostatespecific antigen PSA levels and different types of primary androgen deprivation therapy PADT This study utilized data from the Japan Study Group of Prostate Cancer registry which is a large multicenter populationbased databaseA total of 2982 patients treated with PADT were enrolled Kaplan–Meier analysis was used to compare progressionfree survival PFS and overall survival OS in patients treated using combined androgen blockade CAB and nonCAB therapies The relationships between nadir PSA levels and PADT type according to initial serum PSA levels were also investigatedAmong the 2982 enrolled patients 2101 705 were treated with CAB Although CABtreated patients had worse clinical characteristics their probability of PFS and OS was higher compared with those treated with a nonCAB therapy These results were due to a survival benefit with CAB in patients with an initial PSA level of 500–1000 ng/mL Nadir PSA levels were significantly lower in CAB patients than in nonCAB patients with comparable initial serum PSA levelsA small survival benefit for CAB in metastatic prostate cancer was demonstrated in a Japanese largescale prospective cohort study The clinical significance of nadir PSA levels following PADT was evident but the predictive impact of PSA nadir on OS was different between CAB and nonCAB therapyWe thank Dr Michiyuki Usami Dr Osamu Ogawa Dr Tadaichi Kitamura Dr Kazuhiro Suzuki Dr Taiji Tsukamoto Dr Seiji Naito Dr Yoshihiko Hirao Dr Masaru Murai and the Japan Study Group of Prostate Cancer JCaP for providing clinical data from the JCaP
Keywords: